Physician profile
Luis Hammer
NPI 1801077482
$14,181.42
in general payments reported to CMS, 2019-2025
30 companies · $2,803 in 2025
The $2,803 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,131 · 2022: $3,444 · 2023: $2,617 · 2024: $3,186 · 2025: $2,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,417 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,416.53 |
| Education | $189.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,067.23 | 2021-2025 | |
| Janssen Biotech, INC. | $1,880.82 | 2021-2025 | Tremfya |
| Horizon Therapeutics Plc | $1,778.77 | 2021-2023 | Krystexxa |
| Amgen INC. | $1,567.29 | 2021-2025 | Tavneos, Krystexxa, Evenity |
| Mallinckrodt Hospital Products INC. | $1,154.39 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $1,128.18 | 2021-2025 | Benlysta |
| Ucb, INC. | $963.52 | 2021-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $942.43 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $849.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $591.11 | 2021-2025 | Saphnelo |
| Pfizer INC. | $309.69 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $220.19 | 2021-2025 | Orencia |
| Lilly USA, LLC | $152.03 | 2022-2024 | Taltz, Zepbound |
| Janssen Pharmaceuticals, INC | $99.09 | 2025 | Tremfya |
| Hikma Pharmaceuticals USA | $79.25 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $67.96 | 2024-2025 | |
| Depuy Synthes Sales INC. | $36.76 | 2023-2024 | Orthovisc, Peak, Monovisc |
| Kowa Pharmaceuticals America, INC. | $36.08 | 2022-2023 | Seglentis |
| Actelion Pharmaceuticals US, INC. | $34.45 | 2022 | |
| Invivyd INC | $33.13 | 2025 | Pemgarda |
| Ultragenyx Pharmaceutical INC. | $32.14 | 2021 | |
| Octapharma USA, INC. | $20.56 | 2024 | Octagam Immune Globulin (Human) |
| Collegium Pharmaceutical, INC. | $20.31 | 2023 | Xtampza |
| Redhill Biopharma INC. | $20.30 | 2021 | |
| Valinor Pharma, LLC | $18.34 | 2023 | Movantik |
| Fidia Pharma USA INC. | $18.31 | 2025 | Hymovis, Triluron |
| Alfasigma USA, INC. | $18.09 | 2021 | |
| Aurinia Pharma U.S., INC. | $17.16 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.27 | 2023 | |
| Boston Scientific Corporation | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.